Pfizer Vaccines launches first Centre of Excellence

The University of Louisville has been named as Pfizer’s first ‘Centre of Excellence’, part of its Vaccine Division’s global programme of collaborations with academic institutions to conduct real-world research on vaccine-preventable diseases affecting adults.

The University of Louisville (UofL) will initially conduct two separate, large population-based epidemiological studies in adults – a one-year study of the incidence of infectious diarrhoea with funding provided by Pfizer up to $6.5 million, and a one-year study of the incidence of pneumonia with funding provided by Pfizer up to $4.5 million.

“The Centres of Excellence will complete comprehensive, disease surveillance and real-world vaccine effectiveness studies, which are distinctly different from clinical safety and efficacy research,” said Luis Jodar, Chief Medical and Scientific Affairs Officer at Pfizer Vaccines.

“With strategically located research centres around the world, we anticipate being able to better define and understand global disease burden in adults and vaccine effectiveness, which will help provide robust evidence to national policymakers and health officials who develop recommendations for the use of vaccines in immunisation programs worldwide.”

Julio Ramirez, Chief of UofL Infectious Diseases and Centre Director, said: “To develop a vaccine, it is important to understand the overall population burden of disease that the vaccine is going to prevent: How common is this illness? Who are the patients that are at higher risk?

“These are the questions we will be addressing with the types of studies we are going to be doing in Louisville, Kentucky.”

Pfizer Vaccines is currently planning to establish a few additional Centres of Excellence for epidemiological research strategically located around the world in the coming years. A second global centre anticipated in the first half of 2020.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Joint investment sees UK gov secure pipeline of coronavirus vaccine candidate

The UK government and biotech Valneva have jointly invested in a Scottish facility to bolster vaccine manufacturing capacity. The multi-million-pound investment will allow the government...

Redx out-licenses porcupine inhibitor to AstraZeneca

UK drug discovery and development company, Redx Pharma, has signed a significant out-licensing agreement for its porcupine inhibitor, RXC006, with AstraZeneca. AstraZeneca will take RXC006...

New Chief Medical Officer for Valneva

Valneva, a specialty vaccine company based in France, has appointed Juan Carlos Jaramillo, as Chief Medical Officer and member of the Management Board. Starting 1st...

Majority of top pharma firms report YoY growth in 2019 – data

In 2019, 17 of the top twenty major pharmaceutical players reported year-on-year revenue growth, according to GlobalData. “One winner was Takeda, which saw more than...

Teva & Alvotech join forces to commercialise biosimilars in US

Israel’s Teva Pharmaceutical and Icelandic biopharma Alvotech have entered into an exclusive strategic partnership for the commercialisation in the US of five biosimilar product...

Related news

Blenrep becomes first anti-BCMA approved globally

GlaxoSmithKline (GSK) has secured US approval for Blenrep (belantamab mafodotin-blmf) as a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma. This indication...

Joint investment sees UK gov secure pipeline of coronavirus vaccine candidate

The UK government and biotech Valneva have jointly invested in a Scottish facility to bolster vaccine manufacturing capacity. The multi-million-pound investment will allow the government...

Redx out-licenses porcupine inhibitor to AstraZeneca

UK drug discovery and development company, Redx Pharma, has signed a significant out-licensing agreement for its porcupine inhibitor, RXC006, with AstraZeneca. AstraZeneca will take RXC006...

New Chief Medical Officer for Valneva

Valneva, a specialty vaccine company based in France, has appointed Juan Carlos Jaramillo, as Chief Medical Officer and member of the Management Board. Starting 1st...